Summary & Overview
HCPCS J0225: Injection, vutrisiran, 1 mg
HCPCS Level II code J0225 identifies the injectable agent vutrisiran at a 1 mg dose. Vutrisiran is a specialty RNAi therapeutic used in targeted treatment pathways, and accurate coding for its administration is important for clinical documentation, billing integrity, and payer adjudication across the United States. This code matters nationally because it supports standardized reporting for high-cost, clinically specific biologic therapies and impacts facility and professional billing for outpatient injectable drug delivery.
Key payers evaluated include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J0225 is used in practice, common sites of service where the injection is administered, and what to expect in payer coverage patterns. The publication summarizes available benchmarks for unit reporting, outlines relevant billing considerations, and provides clinical context for use of vutrisiran as an injectable pharmacologic therapy. Data not available in the input is noted where applicable; the focus remains on code definition, service setting, and payer landscape for a national audience.
Billing Code Overview
HCPCS Level II code J0225 denotes Injection, vutrisiran, 1 mg. This code represents a single unit of the prescription biologic agent vutrisiran administered as an injection. The service type is injectable pharmacologic therapy, typically provided as a physician- or clinic-administered drug dose. The typical site of service is an ambulatory infusion clinic, specialty physician office, or outpatient hospital setting where parenteral therapeutic agents are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy who requires parenteral disease-modifying therapy. The patient presents to an outpatient infusion clinic or specialty pharmacy clinic for administration of J0225 (injection, vutrisiran, 1 mg). Prior to administration the clinic verifies diagnosis, obtains baseline laboratory tests (including liver function tests and pregnancy test if applicable), reviews current medications for interactions, and confirms informed consent. The provider documents indication, dose (calculated per product labeling), lot number, and expiration. A licensed clinician or trained RN performs the subcutaneous injection per manufacturer technique, observes the patient for immediate adverse reactions for a monitoring period, and documents post‑administration status and any adverse events. Typical sites of service include outpatient infusion centers, specialty clinic procedure rooms, and hospital outpatient departments. Payors involved in authorization and payment may include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthCare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Modifier not used or unspecified | Rarely used; indicates default billing when no specific modifier applies |